177 related articles for article (PubMed ID: 36265653)
21. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
[TBL] [Abstract][Full Text] [Related]
22. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
23. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
25. Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor.
Scheffschick A; Nenonen J; Xiang M; Winther AH; Ehrström M; Wahren-Herlenius M; Eidsmo L; Brauner H
Front Immunol; 2023; 14():1168684. PubMed ID: 37691935
[TBL] [Abstract][Full Text] [Related]
26. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
[TBL] [Abstract][Full Text] [Related]
27. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways.
Patil K; Kuttikrishnan S; Khan AQ; Ahmad F; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):382-399. PubMed ID: 34906723
[TBL] [Abstract][Full Text] [Related]
28. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
29. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
31. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma.
Günther C; Zimmermann N; Berndt N; Grosser M; Stein A; Koch A; Meurer M
Am J Pathol; 2011 Sep; 179(3):1434-42. PubMed ID: 21741937
[TBL] [Abstract][Full Text] [Related]
34. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
Herrera A; Cheng A; Mimitou EP; Seffens A; George D; Bar-Natan M; Heguy A; Ruggles KV; Scher JU; Hymes K; Latkowski JA; Ødum N; Kadin ME; Ouyang Z; Geskin LJ; Smibert P; Buus TB; Koralov SB
Blood; 2021 Oct; 138(16):1456-1464. PubMed ID: 34232982
[TBL] [Abstract][Full Text] [Related]
35. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.
Lauenborg B; Christensen L; Ralfkiaer U; Kopp KL; Jønson L; Dabelsteen S; Bonefeld CM; Geisler C; Gjerdrum LM; Zhang Q; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
Oncotarget; 2015 Jun; 6(17):15235-49. PubMed ID: 25915535
[TBL] [Abstract][Full Text] [Related]
36. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.
Kamijo H; Miyagaki T; Takahashi-Shishido N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Leukemia; 2020 Mar; 34(3):845-856. PubMed ID: 31712778
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
[TBL] [Abstract][Full Text] [Related]
38. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.
Nicolay JP; Melchers S; Albrecht JD; Assaf C; Dippel E; Stadler R; Wehkamp U; Wobser M; Zhao J; Burghaus I; Schneider S; Gülow K; Goerdt S; Schürch CM; Utikal JS; Krammer PH
Blood; 2023 Aug; 142(9):794-805. PubMed ID: 37217183
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Heterogeneity and the Microbiome of Cutaneous T-Cell Lymphoma.
Licht P; Mailänder V
Cells; 2022 Jan; 11(3):. PubMed ID: 35159138
[TBL] [Abstract][Full Text] [Related]
40. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
